Insider Stock Trading History of Agarwal Sunil


The following table details the trading activities (stock purchases, stock sales, and stock option exercises) reported to the Securities and Exchange Commission (SEC) by insider Agarwal Sunil since year 2005. The trader's CIK number is 1616640. At the time of this reporting, Agarwal Sunil is the President of R & D of Juno Therapeutics, Inc. . (stock ticker symbol JUNO). See this page for all insider trading activities at Juno Therapeutics, Inc. .

Note that in the past AGARWAL SUNIL also reported insider trading activities as an insider of the following companies:
Stock purchases, sales, and option exercises reported by insider Agarwal Sunil since 2005.
  Trade Date   Symbol Company Name (Issuer) Trade Type     Shares       Price ($)   Value ($)
2017-10-02 JUNO Juno Therapeutics, Inc. Sale 7,285 44.76 326,091
2016-07-21 RARE Ultragenyx Pharmaceutical Inc. Sale 649 52.68 34,189
2016-06-20 RARE Ultragenyx Pharmaceutical Inc. Sale 650 54.16 35,204
2016-06-20 RARE Ultragenyx Pharmaceutical Inc. Sale 650 54.16 35,204
2016-06-20 RARE Ultragenyx Pharmaceutical Inc. Sale 650 54.16 35,204
2016-05-24 RARE Ultragenyx Pharmaceutical Inc. Sale 650 66.00 42,900
2016-04-20 RARE Ultragenyx Pharmaceutical Inc. Sale 649 70.53 45,773
2016-03-22 RARE Ultragenyx Pharmaceutical Inc. Sale 650 61.45 39,942
2016-01-20 RARE Ultragenyx Pharmaceutical Inc. Sale 585 72.83 42,605
2015-12-22 RARE Ultragenyx Pharmaceutical Inc. Sale 498 114.81 57,175
2015-11-23 RARE Ultragenyx Pharmaceutical Inc. Sale 498 95.88 47,748
2015-10-20 RARE Ultragenyx Pharmaceutical Inc. Sale 649 85.51 55,495
2015-09-22 RARE Ultragenyx Pharmaceutical Inc. Sale 498 109.51 54,535
2015-08-20 RARE Ultragenyx Pharmaceutical Inc. Sale 17,020 110.67 1,883,654
2015-08-20 RARE Ultragenyx Pharmaceutical Inc. Option Ex 10,000 55.88 558,800

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Agarwal Sunil (President of R & D of Juno Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.